ReviewScience China. Life sciences2021
Current status and future perspectives of immunotherapy in bladder cancer treatment.
Review in Science China. Life sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Efficacy and safety of immunotherapy in anaplastic thyroid carcinoma: a systematic review and meta-analysis.International journal of surgery (London, England) · 2026Pooled it
- What Is-and What Is Not-Immunogenic Cell Death? Functional Definitions, Experimental Standards, and Common Pitfalls.International journal of molecular sciences · 2026Review
- Exploring the underlying mechanisms of Hedyotis diffusa and Scutellaria Barbata herb pair on the prognosis and treatment efficacy of bladder cancer patients: an integrated approach of network pharmacology and bioinformatics analysis.BMC complementary medicine and therapies · 2026Article
- Integrated spatial transcriptome and metabolism study reveals metabolic heterogeneity in human bladder cancer.Cancer gene therapy · 2025Article
- Spatial Transcriptomics Reveals Transcriptomic and Immune Microenvironment Reprogramming during Thyroid Carcinoma Dedifferentiation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- COL6A1 Inhibits the Malignant Development of Bladder Cancer by Regulating FBN1.Cell biochemistry and biophysics · 2025Article
- Potential of CLSPN as a therapeutic target in melanoma: a key player in melanoma progression and tumor microenvironment.Journal of translational medicine · 2025Article
- The interplay between angiogenesis-associated genes and molecular, clinical, and immune features in bladder cancer.Discover oncology · 2025Article
- Integrating Spatial Multi-Omics and Machine Learning to Unravel the Role of PANoptosis in Bladder Cancer Prognosis and Immunotherapy Response.Oncology research · 2025Article
- Key immune cells and their crosstalk in the tumor microenvironment of bladder cancer: insights for innovative therapies.Exploration of targeted anti-tumor therapy · 2025Review
- Identifying functional cuproptosis-related long non-coding RNAs in patients with bladder cancer.Translational cancer research · 2024Article
- Article
- Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75.Cancer cell international · 2024Article
- Dysregulation and antimetastatic function of circLRIG1 modulated by miR-214-3p/LRIG1 axis in bladder carcinoma.Biology direct · 2024Article
- Identification and validation of the nicotine metabolism-related signature of bladder cancer by bioinformatics and machine learning.Frontiers in immunology · 2024Article
- CDK6 as a Biomarker for Immunotherapy, Drug Sensitivity, and Prognosis in Bladder Cancer: Bioinformatics and Immunohistochemical Analysis.International journal of medical sciences · 2024Article
- A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues.Frontiers in immunology · 2024Article
- Knowledge-map analysis of bladder cancer immunotherapy.Human vaccines & immunotherapeutics · 2023Review
- Hypoxia is correlated with the tumor immune microenvironment: Potential application of immunotherapy in bladder cancer.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment strategy of bladder cancer has evolved not only through the traditional modalities of surgery and chemotherapy but also by immunotherapy over the past several decades. Immunotherapies such as intravesical Bacillus Calmette-Guérin (BCG) vaccines and immune checkpoint blockades (ICBs) are sometimes used for treating patients with bladder cancer, especially those who develop resistance to conventional first-line treatments such as surgery and chemotherapy. Unfortunately, it is a limited number of individuals that see clinical benefits from this approach, and complicating matters more is that many of these patients suffer severe immune-related adverse events (irAEs). If current momentum continues to result in improved response rates and managed irAEs, immunotherapy could be poised to revolutionize the landscape of urothelial carcinoma therapeutics.
Indexed as
Identifiers
32926318What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.